<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448708</url>
  </required_header>
  <id_info>
    <org_study_id>012-VWAV06</org_study_id>
    <nct_id>NCT00448708</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access</brief_title>
  <official_title>Trial to Assess the Effectiveness of Maintaining Patency and Safety of the Vascular Wrap Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiotech Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center clinical study in subjects requiring arteriovenous grafts in the upper
      extremity for hemodialysis access. All subjects will provide informed consent before
      undergoing any study procedures. The study will consist of multiple subject visits and
      telephone contacts during the 52 week study period. During the study period subjects must
      also maintain an appropriate hemodialysis schedule.

      IDE Number: G060250
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to an imbalance in graft infections between groups.
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-loss of Target Site Primary Patency</measure>
    <time_frame>1 year</time_frame>
    <description>Subjects had primary patency at the target site from graft placement until an intervention on the target site occurred. The duration between graft implantation and graft abandonment due to loss of patency at the target site was the &quot;time-to-loss of primary patency.&quot; Note: The study was halted early and therefore became underpowered to analyze efficacy as detailed in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>adverse events with at least 5% incidence, reported as number of subjects experiencing the event (rather than total number of events). Adverse events were collected via subject querying at each visit and telephone contact, and by medical record review.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Vascular Wrap and Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifespan® ePTFE Vascular Graft</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular Wrap Paclitaxel-Eluting Mesh</intervention_name>
    <description>0.9 µg/mm^2 paclitaxel</description>
    <arm_group_label>Vascular Wrap and Graft</arm_group_label>
    <other_name>Vascular Wrap</other_name>
    <other_name>paclitaxel mesh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lifespan® ePTFE Vascular Graft</intervention_name>
    <description>vascular graft</description>
    <arm_group_label>Vascular Wrap and Graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lifespan® ePTFE Vascular Graft</intervention_name>
    <description>vascular graft</description>
    <arm_group_label>Lifespan® ePTFE Vascular Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. be ≥ 18 years of age;

          2. if female of childbearing potential, provide evidence of a negative pregnancy test
             within 3 days prior to graft placement (Day -3 to Day 0);

          3. be a candidate for a new end-to-side arteriovenous anastomosis graft placed in the
             upper extremity;

          4. have an outflow vein of greater than or equal to 3 mm in diameter;

          5. be able to effectively communicate with study personnel;

          6. be considered by the physician to be available for subsequent visits;

          7. be willing to comply with all aspects of the treatment and evaluation schedule over a
             52 week duration;

          8. allow representatives of the sponsor, designated CRO, Institutional Review Board
             (IRB), the Ethics Committee, and U.S. Food and Drug Administration (FDA) to review
             his/her relevant medical records;

          9. sign and date an IRB-approved written informed consent prior to initiation of any
             study procedures, including screening procedures;

         10. must agree to participate in protocol 014-VWAV07, a safety study to run consecutively
             for an additional 4 years or until Post-Market Approval (PMA), whichever is longer;
             and

         11. have the Lifespan® ePTFE Vascular Graft successfully implanted.

        Exclusion Criteria:

          1. pregnant, breast-feeding, or female of childbearing potential who do not agree to
             remain abstinent or to use a contraceptive method during the study period.
             Non-childbearing potential is defined as either post-menopausal (amenorrheic for at
             least 1 year) or surgically sterile. Surgically sterile is defined as tubal ligation
             or the absence of the uterus and/or ovaries;

          2. male of childbearing potential, who does not agree to remain abstinent or to use
             contraception to prevent fathering a child during the course of the study.
             Non-childbearing potential is defined as vasectomy or bilateral orchiectomy;

          3. a central venous stenosis on the ipsilateral side is documented;

          4. a hypercoagulable state is documented;

          5. life expectancy is less than one year;

          6. an organ transplant is expected within 6 months of test or control product (study
             products) placement;

          7. hypersensitivity to any component of the study products or procedural materials or
             medications is known;

          8. concurrently involved in another investigational study;

          9. a study product being investigated by others has been received within 30 days prior to
             randomization in this trial;

         10. the study product being studied in this trial has previously been received;

         11. uncontrolled hypertension with systolic BP &gt;200mmHg or diastolic BP &gt;115mmHg is
             present at screening;

         12. currently receiving chemotherapy or radiation therapy; or

         13. placement of a new end-to-end arteriovenous anastomosis graft is required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Avelar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Angiotech Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ladenheim, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centinela Hospital</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC CVTI - Healthcare Consultation II</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Network, LLC</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clincal Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Medical Research Group</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Urological Center, P.A</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida- Research Foundation</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgery Associates</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Care Associates</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington County Hospital Association</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Research Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoracic and Cardiovascular Healthcare Foundation</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Alliance of New York</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRANY - Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates P. C.</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Winston-Salem, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health First Medical Group</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peripheral Vascular Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wisconsin Heart Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <results_first_submitted>June 8, 2011</results_first_submitted>
  <results_first_submitted_qc>October 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2011</results_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vascular Wrap and Graft</title>
          <description>Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh</description>
        </group>
        <group group_id="P2">
          <title>Lifespan® ePTFE Vascular Graft</title>
          <description>Lifespan® ePTFE Vascular Graft Only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not listed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vascular Wrap and Graft</title>
          <description>Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh</description>
        </group>
        <group group_id="B2">
          <title>Lifespan® ePTFE Vascular Graft</title>
          <description>Lifespan® ePTFE Vascular Graft Only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="13.72"/>
                    <measurement group_id="B2" value="61" spread="15.58"/>
                    <measurement group_id="B3" value="63" spread="14.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-to-loss of Target Site Primary Patency</title>
        <description>Subjects had primary patency at the target site from graft placement until an intervention on the target site occurred. The duration between graft implantation and graft abandonment due to loss of patency at the target site was the &quot;time-to-loss of primary patency.&quot; Note: The study was halted early and therefore became underpowered to analyze efficacy as detailed in the protocol.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vascular Wrap and Graft</title>
            <description>Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh</description>
          </group>
          <group group_id="O2">
            <title>Lifespan® ePTFE Vascular Graft</title>
            <description>Lifespan® ePTFE Vascular Graft Only</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-loss of Target Site Primary Patency</title>
          <description>Subjects had primary patency at the target site from graft placement until an intervention on the target site occurred. The duration between graft implantation and graft abandonment due to loss of patency at the target site was the &quot;time-to-loss of primary patency.&quot; Note: The study was halted early and therefore became underpowered to analyze efficacy as detailed in the protocol.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="87" upper_limit="190"/>
                    <measurement group_id="O2" value="159" lower_limit="86" upper_limit="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>adverse events with at least 5% incidence, reported as number of subjects experiencing the event (rather than total number of events). Adverse events were collected via subject querying at each visit and telephone contact, and by medical record review.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vascular Wrap and Graft</title>
            <description>Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh</description>
          </group>
          <group group_id="O2">
            <title>Lifespan® ePTFE Vascular Graft</title>
            <description>Lifespan® ePTFE Vascular Graft Only</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>adverse events with at least 5% incidence, reported as number of subjects experiencing the event (rather than total number of events). Adverse events were collected via subject querying at each visit and telephone contact, and by medical record review.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Number of Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1451"/>
                    <measurement group_id="O2" value="1164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events (deaths only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vascular Wrap and Graft</title>
          <description>Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh</description>
        </group>
        <group group_id="E2">
          <title>Lifespan® ePTFE Vascular Graft</title>
          <description>Lifespan® ePTFE Vascular Graft Only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death unknown cause</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia Alzhemier's type</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Haemorrhage stroke</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>This adverse event resulted in death. Note: In this study, adverse events were never specifically captured as Serious Adverse Events. For this reason, no data other than &quot;adverse events that resulted in death&quot; are available for this category.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="110"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Catheter site hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Generalized oedema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="110"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="110"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Graft hemorrhage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="110"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="110"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="110"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to an observed imbalance in the number of graft infections, enrollment in the 1-year study 012-VWAV06 was suspended at the recommendation of the DSMC. Many of the planned efficacy analyses did not occur as a result of this suspension.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Trudy Estridge</name_or_title>
      <organization>Angiotech Pharmaceuticals</organization>
      <phone>604-221-7676</phone>
      <email>testridge@angio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

